Anticoagulation in acute ischaemic stroke: Deep vein thrombosis prevention and long-term stroke outcomes

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 6 SUPPL. 2, 1999, Pages

  Lensing, A W A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Deep vein thrombosis; Heparin; Ischaemic stroke; Low molecular weight heparin; Thromboprophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BARBITURIC ACID DERIVATIVE; CY 222; DALTEPARIN; DANAPAROID; FIBRINOLYTIC AGENT; GLUTAMATE RECEPTOR ANTAGONIST; HEPARIN; HEPARIN DERIVATIVE; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; MESOGLYCAN; NADROPARIN; SCAVENGER; TINZAPARIN; WARFARIN;

BLEEDING; BLOOD CLOT LYSIS; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTICOAGULANTS; CEREBROVASCULAR ACCIDENT; HUMANS; ISCHEMIA; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0032851336     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-1276.
2. Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342-344.
3. Kay R, Wong KS. Pilot study of low-molecular-weight heparin in the treatment of acute ischemic stroke. Stroke 1994; 25: 684-685.
4. Camarata PJ, Heros RC, Latchaw RE. Brain attack: The rationale for treating stroke as a medical emergency. Neurosurgery 1994; 34: 144-158.
5. International Stroke Trial Collaborative Group. The International Stroke Trial (TST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.
6. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: a randomised placebo-controlled trial of early aspirin use in 2000 patients with acute ischaemic stroke. Lancet 1997; 849: 1641-1649.
7. Kelly BJ, Luce JM. Current concepts in vertebral protection. Chest 1993; 103: 1246-1254.
8. Hall E, Pazara K, Braughler JM. Nonsteroidal lazaroid U78517F in models of focal and global ischaemia. Stroke 1990; 21: 1183-1187.
9. Boysen G, Overgaard K. Thrombolysis in ischaemic stroke - how far from a clinical breakthrough? J Intern Med 1995; 237: 95-103.
10. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 1995; 333: 1581-1587.
11. Hacke W, Kaste M, Fieschi C, von Kummer R, Devalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasia Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251.
12. Dumas R, Woitinas F, Kutnowski M, Nikolic I, Berberish R, Abedinpour F, et al. A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke. Age Ageing 1994; 23: 512-516.
13. Brown M, Glassenberg M. Mortality factors in patients with acute stroke. JAMA 1973; 224: 1493-1495.
14. Bounds JV, Wiebers DO, Whisnant JP, Okazaki H. Mechanisms and timing of deaths from cerebral infarction. Stroke 1981; 12: 474-477.
15. Warlow C, Ogston D, Douglas AS. Venous thrombosis following stroke. Lancet 1972; i: 1305-1306.
16. Treatment of deep vein thrombosis following stroke 16. McCarthy ST, Robertson D, Turner JJ, Hawley CJ. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet 1977; ii: 800-801.
17. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing 1986; 15: 84-88.
18. Landi G, D'Angclo A, Boccardi E, Candelise L, Mannucci PM, Morabit A, Orazio EM. Venous thromboembolism in acute stroke: prognostic importance of hypercoagulability. Arch Neurol 1992; 49: 279-283.
19. Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Semin Thromb Hemost 1990; 16 (suppl): 25-33.
20. Sandercock PAG, Van den Belt GM, Lindley RI, Slattery J. Antithrombotic therapy in acute ischemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993; 56: 17-25
21. Counsell C, Sandercock P. Use of anticoagulants in patients with acute ischemic stroke [letter]. Stroke 1995; 26: 522-523.
22. Leizorovicz A, Hauch MC, Chapuis F-R, Samama MM, Boissel J-P. Low molecular weight heparin in the prevention of perioperiative thrombosis. BMJ 1992; 305: 913-920.
23. Hirsh J. Overview of low molecular weight heparins and heparinoids: basic and clinical aspects. Aust NZ J Med 1992; 22: 487-495
24. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, et al. Double-blind, randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep vein thrombosis in thrombotic stroke. Lancet 1987; i: 523-526.
25. Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJH. Prophylaxis of deep vein thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin®) in stroke patients. Haemostasis 1989; 19: 245-250.
26. Cazzato G, Zorzon M, Mase G, Antonutti L, Iona LG. Mesoglycan in acute focal cerebral ischemia. [Article in Italian] Riv Neurol 1989; 59: 121-126.
27. Elias A, Milandre L, Lagrange G, Aillaud MF, Alonzo B, Toulemonde F, et al. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients). [Article in French]. Rev Med Interne 1990; 11: 95-98.
28. Kay R, Wong SK, Yu YL, Chan YW, Tsoi TH, Ahuja AT, et al. Low-molecular weight heparin for the treatment of acute ischaemic stroke. N Engl J Med 1995; 333: 1588-1593.
29. The TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. JAMA 1998; 279: 1265-1272.